Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.45 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038790 | 0.88 | CHKA (0.59) | KDM4ECHKASMN1; SMN2MAPK1SYK | |
| SCHEMBL3569140 | 0.87 | CHKA (0.60) | KDM4ECHKASMN1; SMN2MAPK1SYK | |
| Hydrochloric Acid SCHEMBL19585072 | 0.85 | CHKA (0.59) | KDM4ECHKASMN1; SMN2MAPK1SYK | |
| Hydrochloric Acid SCHEMBL10900610 | 0.85 | CHKA (0.59) | KDM4ECHKASMN1; SMN2MAPK1SYK | |
| SCHEMBL3036998 | 0.82 | CHKA (0.62) | KDM4ECHKASMN1; SMN2MAPK1SYK | |
| Hydrochloric Acid SCHEMBL20305004 | 0.81 | CXCR4 (0.62) | KDM4ECHKASMN1; SMN2MAPK1SYK | |
| Tert-Butyl Formate SCHEMBL28272976 | 0.77 | CHKA (0.50) | KDM4ECHKASMN1; SMN2MAPK1SYK | |
| SCHEMBL28403717 | 0.76 | KCNJ1 (0.52) | KDM4ECHKAMAPTATM | |
| SCHEMBL20333527 | 0.76 | MLNR (0.55) | KDM4ECHKASMN1; SMN2MAPK1MEN1 | |
| SCHEMBL24673257 | 0.75 | LMNA (0.57) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319181-A1 | Method of Making an Artificial Nuclease for Anti-viral, Anti-bacterial Applications | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2008-12-25 | — | — | US | disclosed |
| US-20060094045-A1 | Macrocyclic chelators for gene-silencing or gene disruption | NAVY, THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094045-A1 | Macrocyclic chelators for gene-silencing or gene disruption | ZFR, CTCF, L3MBTL1 | CHRM3 4868/4885CHRM1 4876/4885KDM4E 2610/4885 |
| US-20080319181-A1 | Method of Making an Artificial Nuclease for Anti-viral, Anti-bacterial Applications | POLN, NSUN2, POLM | CHRM3 4314/4885CHRM1 4065/4885KDM4E 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.